Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Innoviva, Inc.
Exploring the continued controversy around the 340B US federal drug discount program. As the story moves into 2022, key questions remain unanswered.
The companies announced a strategic collaboration to integrate Stryker’s neurovascular instruments with Microbot’s Liberty robot to create procedure kits specifically for neurovascular interventions.
Private Company Edition: Newpath Partners’ second fund totals $350m, Merck KGaA committed €600m to M Ventures, Eir Ventures raised €122.3m and Breakout Ventures has $112.5m. Recent financings were led by SOTIO ($317.5m), Odyssey ($218m), Avistone ($200m) and Acepodia ($109m).
Private Company Edition: Recent VC financings across biopharma sectors include three major mega-rounds as Generate Biomedicines bringing in $370m, followed by $250m for Acelyrin and $125m for Chroma Medicine. Also, Treadwell raised a $91m series B and Ncardia brought in $60m-plus.
- Other Names / Subsidiaries
- Innoviva Strategic Opportunities LLC
- Theravance, Inc.